Contact
Please use this form to send email to PR contact of this press release:
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
TO:
Please use this form to send email to PR contact of this press release:
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
TO: